Ewing Sarcoma of the Head and Neck: Analysis of 183 Cases With Comparison to Non–Head and Neck Sites. (March 2017)

• Record Type: Journal Article
• Authors: Ellis, Mark A.; Gerry, Daniel R.; Neskey, David M.; Lentsch, Eric J.
• Is Part Of: Annals of otology, rhinology & laryngology. Volume 126:Number 3(2017:Mar.)
• Page Start: 179
• Page End: 184
• Publication Date: 2017-03
• Subjects: Ewing sarcoma -- head and neck -- SEER -- survival; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1177/0003489416681322
• Languages: English
• ISSNs: 0003-4894

Abstract

Objectives: Ewing sarcoma is a rare tumor of the head and neck. Previous efforts to characterize Ewing sarcoma of the head and neck (ES-HN) have been limited to small retrospective series. The objective of this study was to analyze the demographic, clinicopathologic, treatment, and survival characteristics of ES-HN compared to Ewing sarcoma at other locations (ES-other). Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, we compared 183 patients with ES-HN to 3177 patients with ES-other. Patient characteristics were analyzed with chi-square or t test. Ten-year disease-specific survival (DSS) and overall survival (OS) were estimated via the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox regression analysis was used to determine if HN location was an independent prognosticator. Results: The ES-HN displayed a lower tumor size ( P < .001) and metastatic rate ( P < .001) compared to ES-other. The ES-HN had a better 10-year DSS and OS than ES-other ( P = .001, P = .015, respectively). The HN location did not achieve statistical significance on multivariate Cox regression analysis ( P = .88). Conclusion: ES-HN does not appear to be a separate clinical entity compared to ES-other; rather, its associated improved prognosis is likely secondary to its smaller size and lower metastatic rate compared to ES-other.